1. Home
  2. VOC vs IMMP Comparison

VOC vs IMMP Comparison

Compare VOC & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VOC

VOC Energy Trust Units of Beneficial Interest

HOLD

Current Price

$3.30

Market Cap

58.6M

Sector

Energy

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.46

Market Cap

58.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VOC
IMMP
Founded
2010
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.6M
58.2M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
VOC
IMMP
Price
$3.30
$0.46
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$5.50
AVG Volume (30 Days)
106.7K
22.8M
Earning Date
01-01-0001
05-12-2026
Dividend Yield
12.46%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$445.09
Revenue Next Year
N/A
N/A
P/E Ratio
$6.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.60
$0.29
52 Week High
$3.84
$3.53

Technical Indicators

Market Signals
Indicator
VOC
IMMP
Relative Strength Index (RSI) 43.75 33.45
Support Level $3.24 $0.29
Resistance Level $3.31 $1.81
Average True Range (ATR) 0.15 0.09
MACD -0.01 0.04
Stochastic Oscillator 35.42 5.54

Price Performance

Historical Comparison
VOC
IMMP

About VOC VOC Energy Trust Units of Beneficial Interest

VOC Energy Trust is a statutory trust. It is created to acquire and hold a term net profits interest for the benefit of the Trust unitholders. The underlying properties include VOC Brazos' net interests which are located in the states of Kansas and Texas. The trust is entitled to receive the net proceeds from the sale of production of oil and natural gas attributable to the underlying properties. The business and affairs of the Trust are managed by the Trustee, and neither VOC Brazos nor any of its affiliates has the ability to manage or influence the operations of the Trust.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: